Stanford pledges doc-payment disclosure

Stanford University's medical school will begin to publicly identify doctors and other faculty members who receive more than $5,000 annually from drug and medical-device companies--but it won't put an exact figure on how much they were paid. Report

Suggested Articles

The real estate impresario that built a chain of upscale drug recovery facilities is now building a gene and cell therapy CDMO near Philadelphia.

The seven-year Astellas venture served as a model for Amgen's recent $2.7 billion tie-up with BeiGene in China—and now it's amping up there, too.

After a jury ordered Gilead's Kite Pharma to pay $752 million for CAR-T patent infringement, BMS is asking for punitive damages in that amount, too.